Invitae, which offers a broad suite of genetic tests as a single service at a low price, raised $102 million by offering 6.35 million shares at $16. The company originally planned to offer 5.35 million shares at a range of $13 to $15. At the new terms,...read more
AutoGenomics, which sells a molecular diagnostics system for genetic testing in clinical laboratories, announced terms for its IPO on Monday. The Vista, CA-based company plans to raise $45 million by offering 3.8 million shares at a price range of $11 to $13....read more
Invitae, which consolidates available genetic tests into a single service, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The San Francisco, CA-based company, which was founded in 2010 and booked $800,000 in sales...read more
GenMark Diagnostics, which offers a molecular diagnostics testing system to hospitals and labs, will see its quiet period end on Tuesday, July 6th. On May 27th, the company raised $27.6 million by offering 4.6 million shares at $6, below the range of $8-$10. ...read more
Aced the gene test: Invitae prices upsized IPO above range at $16
Invitae, which offers a broad suite of genetic tests as a single service at a low price, raised $102 million by offering 6.35 million shares at $16. The company originally planned to offer 5.35 million shares at a range of $13 to $15. At the new terms,...read more
Genetic diagnostics company AutoGenomics sets terms for $45 million IPO
AutoGenomics, which sells a molecular diagnostics system for genetic testing in clinical laboratories, announced terms for its IPO on Monday. The Vista, CA-based company plans to raise $45 million by offering 3.8 million shares at a price range of $11 to $13....read more
Genetic testing company Invitae files for an $86 million IPO
Invitae, which consolidates available genetic tests into a single service, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The San Francisco, CA-based company, which was founded in 2010 and booked $800,000 in sales...read more
GenMark Diagnostic quiet period ends July 6
GenMark Diagnostics, which offers a molecular diagnostics testing system to hospitals and labs, will see its quiet period end on Tuesday, July 6th. On May 27th, the company raised $27.6 million by offering 4.6 million shares at $6, below the range of $8-$10. ...read more